Last reviewed · How we verify
dipirone
Dipirone, marketed by Hospital Central Dr. Luis Ortega, is an established product with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | dipirone |
|---|---|
| Also known as | Both groups received dipirone |
| Sponsor | Hospital Central Dr. Luis Ortega |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Fixed Combination of Dipirone and Codeine Compared to the Isolated Use of Dipyrone and Codeine in Controlling Pain After Pelvic-abdominal Surgery. (PHASE3)
- Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dipirone CI brief — competitive landscape report
- dipirone updates RSS · CI watch RSS
- Hospital Central Dr. Luis Ortega portfolio CI